Do analysts recommend ANTX or AVTE?

Anthem presently has a consensus price target of $9.00, indicating a potential upside of 73.08%. Given Anthem's stronger consensus rating and higher probable upside, equities analysts plainly believe Anthem is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anthem 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, ANTX or AVTE?

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anthem N/A N/A -$35.17M -$1.10 N/A Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A

Is ANTX or AVTE more profitable?

Anthem's return on equity of -52.35% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Anthem N/A -52.35% -47.25% Aerovate Therapeutics N/A -90.19% -77.47%

Do analysts recommend ANTX or SBTX?

Anthem currently has a consensus target price of $9.00, indicating a potential upside of 73.08%. Given Anthem's stronger consensus rating and higher possible upside, equities analysts clearly believe Anthem is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anthem 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings & valuation, ANTX or SBTX?

Anthem is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anthem N/A N/A -$35.17M -$1.10 N/A Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A

Is ANTX or SBTX more profitable?

Silverback Therapeutics' return on equity of -29.62% beat Anthem's return on equity. Company Net Margins Return on Equity Return on Assets Anthem N/A -52.35% -47.25% Silverback Therapeutics N/A -29.62% -28.20%

Do analysts recommend ELYM or ANTX?

Anthem has a consensus price target of $9.00, indicating a potential upside of 73.08%. Given Anthem's stronger consensus rating and higher possible upside, analysts clearly believe Anthem is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Anthem 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings & valuation, ELYM or ANTX?

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A Anthem N/A N/A -$35.17M -$1.10 N/A

Is ELYM or ANTX more profitable?

Eliem Therapeutics' return on equity of -47.03% beat Anthem's return on equity. Company Net Margins Return on Equity Return on Assets Eliem Therapeutics N/A -47.03% -45.97% Anthem N/A -52.35% -47.25%

Do analysts rate ANTX or LWAC?

Anthem currently has a consensus target price of $9.00, indicating a potential upside of 73.08%. Given Anthem's stronger consensus rating and higher probable upside, equities research analysts plainly believe Anthem is more favorable than LightWave Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anthem 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 LightWave Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, ANTX or LWAC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anthem N/A N/A -$35.17M -$1.10 N/A LightWave Acquisition N/A N/A N/A N/A N/A

Is ANTX or LWAC more profitable?

LightWave Acquisition's return on equity of 0.00% beat Anthem's return on equity. Company Net Margins Return on Equity Return on Assets Anthem N/A -52.35% -47.25% LightWave Acquisition N/A N/A N/A

Do analysts prefer NLTX or ANTX?

Anthem has a consensus price target of $9.00, indicating a potential upside of 73.08%. Given Anthem's stronger consensus rating and higher possible upside, analysts plainly believe Anthem is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Anthem 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings & valuation, NLTX or ANTX?

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A Anthem N/A N/A -$35.17M -$1.10 N/A

Is NLTX or ANTX more profitable?

Neoleukin Therapeutics' return on equity of -37.22% beat Anthem's return on equity. Company Net Margins Return on Equity Return on Assets Neoleukin Therapeutics N/A -37.22% -30.91% Anthem N/A -52.35% -47.25%

Anthem (ANTX) Competitors

$5.20 +0.06 (+1.17%)

Closing price 04:00 PM Eastern

Extended Trading

$5.14 -0.06 (-1.06%)

As of 04:31 PM Eastern

Compare

ANTX vs. AVTE, SBTX, ELYM, LWAC, and NLTX

Should you buy Anthem stock or one of its competitors? MarketBeat compares Anthem with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Anthem include Aerovate Therapeutics (AVTE), Silverback Therapeutics (SBTX), Eliem Therapeutics (ELYM), LightWave Acquisition (LWAC), and Neoleukin Therapeutics (NLTX).

How does Anthem compare to Aerovate Therapeutics?

Anthem (NASDAQ:ANTX) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

90.5% of Anthem shares are owned by institutional investors. 24.5% of Anthem shares are owned by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anthem	N/A	N/A	-$35.17M	-$1.10	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

In the previous week, Anthem had 1 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 1 mentions for Anthem and 0 mentions for Aerovate Therapeutics. Anthem's average media sentiment score of 1.87 beat Aerovate Therapeutics' score of 0.00 indicating that Anthem is being referred to more favorably in the media.

Company	Overall Sentiment
Anthem	Very Positive
Aerovate Therapeutics	Neutral

Anthem has a beta of -0.98, meaning that its stock price is 198% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

Anthem presently has a consensus price target of $9.00, indicating a potential upside of 73.08%. Given Anthem's stronger consensus rating and higher probable upside, equities analysts plainly believe Anthem is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anthem	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Anthem's return on equity of -52.35% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anthem	N/A	-52.35%	-47.25%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

Summary

Anthem beats Aerovate Therapeutics on 10 of the 12 factors compared between the two stocks.

How does Anthem compare to Silverback Therapeutics?

Anthem (NASDAQ:ANTX) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

90.5% of Anthem shares are owned by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are owned by institutional investors. 24.5% of Anthem shares are owned by company insiders. Comparatively, 34.4% of Silverback Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Anthem currently has a consensus target price of $9.00, indicating a potential upside of 73.08%. Given Anthem's stronger consensus rating and higher possible upside, equities analysts clearly believe Anthem is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anthem	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Anthem has a beta of -0.98, meaning that its share price is 198% less volatile than the broader market. Comparatively, Silverback Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market.

In the previous week, Anthem had 1 more articles in the media than Silverback Therapeutics. MarketBeat recorded 1 mentions for Anthem and 0 mentions for Silverback Therapeutics. Anthem's average media sentiment score of 1.87 beat Silverback Therapeutics' score of 0.00 indicating that Anthem is being referred to more favorably in the media.

Company	Overall Sentiment
Anthem	Very Positive
Silverback Therapeutics	Neutral

Anthem is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anthem	N/A	N/A	-$35.17M	-$1.10	N/A
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

Silverback Therapeutics' return on equity of -29.62% beat Anthem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anthem	N/A	-52.35%	-47.25%
Silverback Therapeutics	N/A	-29.62%	-28.20%

Summary

Anthem beats Silverback Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Anthem compare to Eliem Therapeutics?

Eliem Therapeutics (NASDAQ:ELYM) and Anthem (NASDAQ:ANTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Eliem Therapeutics has a beta of -0.39, suggesting that its share price is 139% less volatile than the broader market. Comparatively, Anthem has a beta of -0.98, suggesting that its share price is 198% less volatile than the broader market.

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
Anthem	N/A	N/A	-$35.17M	-$1.10	N/A

69.8% of Eliem Therapeutics shares are owned by institutional investors. Comparatively, 90.5% of Anthem shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by insiders. Comparatively, 24.5% of Anthem shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Anthem had 1 more articles in the media than Eliem Therapeutics. MarketBeat recorded 1 mentions for Anthem and 0 mentions for Eliem Therapeutics. Anthem's average media sentiment score of 1.87 beat Eliem Therapeutics' score of 0.00 indicating that Anthem is being referred to more favorably in the news media.

Company	Overall Sentiment
Eliem Therapeutics	Neutral
Anthem	Very Positive

Eliem Therapeutics' return on equity of -47.03% beat Anthem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
Anthem	N/A	-52.35%	-47.25%

Anthem has a consensus price target of $9.00, indicating a potential upside of 73.08%. Given Anthem's stronger consensus rating and higher possible upside, analysts clearly believe Anthem is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Anthem	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Anthem beats Eliem Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Anthem compare to LightWave Acquisition?

Anthem (NASDAQ:ANTX) and LightWave Acquisition (NASDAQ:LWAC) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

90.5% of Anthem shares are held by institutional investors. 24.5% of Anthem shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Anthem and Anthem both had 1 articles in the media. Anthem's average media sentiment score of 1.87 equaled LightWave Acquisition'saverage media sentiment score.

Company	Overall Sentiment
Anthem	Very Positive
LightWave Acquisition	Very Positive

Anthem currently has a consensus target price of $9.00, indicating a potential upside of 73.08%. Given Anthem's stronger consensus rating and higher probable upside, equities research analysts plainly believe Anthem is more favorable than LightWave Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anthem	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
LightWave Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

LightWave Acquisition's return on equity of 0.00% beat Anthem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anthem	N/A	-52.35%	-47.25%
LightWave Acquisition	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anthem	N/A	N/A	-$35.17M	-$1.10	N/A
LightWave Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

Anthem beats LightWave Acquisition on 5 of the 7 factors compared between the two stocks.

How does Anthem compare to Neoleukin Therapeutics?

Neoleukin Therapeutics (NASDAQ:NLTX) and Anthem (NASDAQ:ANTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Anthem has a consensus price target of $9.00, indicating a potential upside of 73.08%. Given Anthem's stronger consensus rating and higher possible upside, analysts plainly believe Anthem is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Anthem	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
Anthem	N/A	N/A	-$35.17M	-$1.10	N/A

Neoleukin Therapeutics' return on equity of -37.22% beat Anthem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Anthem	N/A	-52.35%	-47.25%

Neoleukin Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Anthem has a beta of -0.98, meaning that its stock price is 198% less volatile than the broader market.

52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 90.5% of Anthem shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by insiders. Comparatively, 24.5% of Anthem shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Anthem had 1 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 1 mentions for Anthem and 0 mentions for Neoleukin Therapeutics. Anthem's average media sentiment score of 1.87 beat Neoleukin Therapeutics' score of 0.00 indicating that Anthem is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
Anthem	Very Positive

Summary

Anthem beats Neoleukin Therapeutics on 9 of the 12 factors compared between the two stocks.

Get Anthem News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANTX vs. The Competition

Export

Metric	Anthem	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$185.12M	$979.79M	$6.79B	$12.17B
Dividend Yield	N/A	4.84%	2.68%	5.91%
P/E Ratio	N/A	1.50	25.79	24.19
Price / Sales	N/A	129.09	519.93	82.79
Price / Cash	N/A	20.06	46.33	53.91
Price / Book	2.68	8.01	10.77	6.37
Net Income	-$35.17M	-$4.05M	$3.57B	$337.69M
7 Day Performance	4.00%	0.56%	3.15%	-0.30%
1 Month Performance	9.94%	1.25%	2.33%	0.36%
1 Year Performance	381.48%	47.33%	33.42%	26.94%

Anthem Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANTX Anthem	2.6945 of 5 stars	$5.20 +1.2%	$9.00 +73.1%	+367.3%	$185.12M	N/A	N/A	N/A	Positive News High Trading Volume
AVTE Aerovate Therapeutics	N/A	$16.82 -0.3%	N/A	+109.0%	$487.53M	N/A	N/A	20	High Trading Volume
SBTX Silverback Therapeutics	N/A	$9.90 +2.1%	N/A	-37.2%	$356.97M	N/A	N/A	83	Gap Down High Trading Volume
ELYM Eliem Therapeutics	N/A	$11.34 +5.9%	N/A	+888.4%	$337.39M	N/A	N/A	9
LWAC LightWave Acquisition	N/A	$10.24 +0.2%	N/A	N/A	$307.87M	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANTX) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anthem (ANTX) Competitors

ANTX vs. AVTE, SBTX, ELYM, LWAC, and NLTX

How does Anthem compare to Aerovate Therapeutics?

Summary

How does Anthem compare to Silverback Therapeutics?

Summary

How does Anthem compare to Eliem Therapeutics?

Summary

How does Anthem compare to LightWave Acquisition?

Summary

How does Anthem compare to Neoleukin Therapeutics?

Summary

Media Sentiment Over Time

ANTX vs. The Competition

Anthem Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anthem (ANTX) Competitors

ANTX vs. AVTE, SBTX, ELYM, LWAC, and NLTX

How does Anthem compare to Aerovate Therapeutics?

Do institutionals & insiders believe in ANTX or AVTE?

Which has better valuation and earnings, ANTX or AVTE?

Does the media favor ANTX or AVTE?

Which has more volatility and risk, ANTX or AVTE?

Do analysts recommend ANTX or AVTE?

Is ANTX or AVTE more profitable?

Summary

How does Anthem compare to Silverback Therapeutics?

Do institutionals and insiders believe in ANTX or SBTX?

Do analysts recommend ANTX or SBTX?

Which has more volatility & risk, ANTX or SBTX?

Does the media refer more to ANTX or SBTX?

Which has higher earnings & valuation, ANTX or SBTX?

Is ANTX or SBTX more profitable?

Summary

How does Anthem compare to Eliem Therapeutics?

Which has more risk and volatility, ELYM or ANTX?

Which has higher earnings & valuation, ELYM or ANTX?

Do institutionals & insiders believe in ELYM or ANTX?

Does the media prefer ELYM or ANTX?

Is ELYM or ANTX more profitable?

Do analysts recommend ELYM or ANTX?

Summary

How does Anthem compare to LightWave Acquisition?

Do insiders & institutionals believe in ANTX or LWAC?

Does the media prefer ANTX or LWAC?

Do analysts rate ANTX or LWAC?

Is ANTX or LWAC more profitable?

Which has stronger earnings & valuation, ANTX or LWAC?

Summary

How does Anthem compare to Neoleukin Therapeutics?

Do analysts prefer NLTX or ANTX?

Which has higher earnings & valuation, NLTX or ANTX?

Is NLTX or ANTX more profitable?

Which has more risk & volatility, NLTX or ANTX?

Do institutionals and insiders believe in NLTX or ANTX?

Does the media refer more to NLTX or ANTX?

Summary

Media Sentiment Over Time

ANTX vs. The Competition

Anthem Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools